Stay updated with breaking news from Pivotal Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024; Potential to be First Approved Treatment for GBS Patients in the…
CMPS earnings call for the period ending December 31, 2022.
/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced its intention to file a Biologics License Application (BLA) in 2024 using the FDA's accelerated...
Press release content from Business Wire. The AP news staff was not involved in its creation.
Press release content from Business Wire. The AP news staff was not involved in its creation.